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pressure of 170/100 mm Hg without orthostatic changes. Perti-
nent findings included trace edema, hyperpigmented and raised
plaques on the upper body and arms, and cardiomegaly. Nei-
ther hepatosplenomegaly nor lymphadenopathy was present.
Urinalysis revealed 41 proteinuria and a negative sediment.
Laboratory examination demonstrated a serum creatinine of
4.9 mg/dl and a CD4 count of 20 cells/ml. Red blood cell mor-
phology, platelet count, and bleeding time were normal. A 24-
hour urine collection contained 4.7 g of protein. Creatinine
clearance was 15 cc/min. Antibodies to hepatitis B and C were
negative; the ANA was negative and serum complement was
normal. The HIV-1 RNA, quantitated by RT-PCR, was 1.4 3
103 copies/ml. A renal biopsy revealed collapsing focal glomeru-
losclerosis, extensive focal glomerulosclerosis, and extensive
microcystic tubulointerstitial disease. There were no tubulore-
ticular structures, and immune complexes were not detected.CASE PRESENTATION
The biopsy was consistent with HIV-associated nephropathy.
A 37-year-old African-American man, HIV seropositive The patient’s serum creatinine rose to 6.7 mg/dl; a percutaneous
since 1986 and a former injection drug user, was referred to vascular access was placed, a PTFE graft inserted, and hemodi-
the Division of Nephrology of Mt. Sinai Medical Center for alysis initiated.
evaluation of proteinuria and azotemia. He had been asymp- The patient remained stable on hemodialysis. Four months
tomatic and never hospitalized until three years ago, when he after initiation of dialysis, saquinavir (a protease inhibitor) was
presented to Mt. Sinai Medical Center for the first time with added to the two reverse transcriptase inhibitors because of
a fever and headache. Workup at that time included multiple the persistently low CD4 count and viral burden. After six
blood cultures, CAT scan, and lumbar puncture. Significant months of triple-drug therapy, the patient, on his own initiative,
findings included hypertension (160/100 mm Hg); oral thrush; stopped taking all antiretroviral medications. One month later,
serum creatinine, 1.2 mg/dl; urine protein, 700 mg/24 hrs; and when he returned to the clinic, the CD4 count was 30 cells/ml,
a CD4 count of 30 cells/ml. His fever and headache resolved and the plasma RNA level was 1.1 3 105 copies/ml. After lengthy
during hospitalization, and he was discharged on clotrimazole, discussions with his physicians, the patient restarted his triple-
fluconazole, and amlodipine with plans for followup in the drug regimen. Shortly thereafter, he noticed that his urine
AIDS clinic. output had increased, and he returned to the clinic one month
He was not seen again until two years ago, when he presented later. His predialysis creatinine was stable at 4 mg/dl; the creati-
to the AIDS clinic with weakness and pruritic skin lesions. The nine clearance was 30 ml/min. Dialysis was discontinued, and
blood pressure was 140/105 mm Hg; CD4 count, 20 cells/ml; a repeat renal biopsy was essentially unchanged. The CD4
serum creatinine, 3.0 mg/dl; and 41 proteinuria by dipstick. count was 20 cells/ml, and the viral load was 1.3 3 105/ml.
Therapy with AZT, 3TC (a reverse transcriptase inhibitor), and The patient remains off dialysis, and his new antiretroviral
trimethoprim-sulfamethoxazole was initiated, and the patient regimen includes nelfinavir (a protease inhibitor), D4T (a reverse
was referred to the Nephrology Clinic. transcriptase inhibitor), and 3TC. Two months ago, his CD4
On examination in the Nephrology Clinic one month later, count was 80 cells/ml and his viral burden 2.8 3 103 copies/ml.he complained of general malaise, weakness, fatigue, anorexia,
and pruritus. Physical examination revealed a well-developed
but ill-appearing black male. He was afebrile with a blood DISCUSSION
Dr. Paul E. Klotman (Professor of Medicine, Chief,
Presentation of this Forum is made possible by grants from Merck and Division of Nephrology; Vice Chairman for Research,Co., Incorporated; Astra Pharmaceuticals; Hoechst Marion Roussel,
Department of Medicine, Mt. Sinai School of Medicine,Incorporated; Amgen, Incorporated; Dialysis Clinic, Incorporated; and
R & D Laboratories, Incorporated. New York, New York, USA): The patient today is similar
in most ways to patients who present with human immu-Key words: AIDS, end-stage renal failure, acute renal failure, focal
nodeficiency virus (HIV)-associated nephropathy. He issegmental glomerulopathy, microcystic tubulointerstitial disease, col-
lapsing glomerulopathy. a black male with a history of intravenous drug use from
an urban center, New York City. He developed signifi- 1999 by the International Society of Nephrology
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cant proteinuria and had a rapidly progressive clinical larly those with AIDS, present with acute renal failure
[2–5]. Patients with AIDS experience recurrent infec-course. His only atypical clinical feature is the presence
of hypertension; most patients with HIV-associated ne- tions and are exposed to multiple drugs including poten-
tially nephrotoxic antivirals [6–11], and they are at greatphropathy (HIVAN) are volume depleted and tend to
have normal or low systemic blood pressure. His CD41 risk for developing acute renal failure from the many
usual causes. In addition, AIDS patients tend to be vol-count of 30 cells/ml defines him as an AIDS patient rela-
tively late in the course of his disease. His HIV RNA ume depleted as a result of salt wasting, poor nutrition,
nausea, or vomiting, and volume depletion is an impor-level of 2.8 3 103 copies/ml on the triple therapy repre-
sents a 2 log decrease from the untreated level, but he tant predisposing factor for acute renal injury from all
causes [2, 3, 5, 12–22]. In contrast, HIVAN is a diseasehas never achieved an optimal response, suppression to
nondetectable levels of viral RNA. His clinical course of progressive renal failure with both tubulointerstitial
and glomerular components [2, 12, 23–32]. Thus, HIV-1-raises the possibility that antiviral agents were effective
therapy for his HIVAN, but the patient might have had infected patients with acute renal failure should be ap-
proached like any patient with a change in renal function.a reversible injury superimposed on a background of
HIVAN that resolved spontaneously. This patient clearly The diagnosis of HIVAN, however, should be enter-
tained in seropositive patients with proteinuria and evi-demonstrates the need for controlled trials when propos-
ing novel therapeutic interventions. dence of declining GFR over time.
The clinical course of HIVAN has changed very littleThis is not the first Nephrology Forum dedicated to
HIVAN. In 1990, a Forum was dedicated to the renal from its early descriptions [2, 32–36]. Occurring almost
exclusively in seropositive black patients, HIVAN occa-complications of HIV-1 [1]. At that time, HIVAN was
a rare disease; fewer than 200 cases were reported by sionally affects Hispanics [37] and very rarely, if ever,
whites. Approximately 50% of HIVAN patients have athe United States Renal Data System (USRDS). To put
this case number in perspective, at the time of that Forum history of intravenous drug use. Most patients present
with proteinuria and reduced renal function. The pro-nine years ago, only 115,000 cases of AIDS had been
reported by the Centers for Disease Control (CDC) in teinuria can range from modest (0.5 to 1.5 g protein/24
hours) to nephrotic levels. In the early descriptions ofthe entire United States. As of 1998, the City of New
York alone reported just over 100,000 cases of AIDS HIVAN, the disease was thought to occur at any stage
of HIV infection. Since the change in the diagnostic(New York City Department of Health, Office of AIDS
Surveillance). criteria for AIDS, however, most patients present late
in the course of their HIV-1 infection [38, 39]. MostIn the past nine years, the HIV epidemic has changed
dramatically. Some of these changes have important im- HIVAN patients already have experienced an AIDS-
defining condition or already have a CD41 cell count lessplications for the demographics of renal disease in this
country. Blacks and Hispanics have become the racial than 250 cells/mm3 [39]. Suggestive features of HIVAN
include the presence of renal tubular epithelial cells inpopulations at greatest risk for AIDS in the United States.
Heterosexual contact and intravenous drug use have be- the urinary sediment and normal to enlarged echogenic
kidneys despite significant renal insufficiency. Hyperten-come the most important routes for HIV infection. Thus,
the population at greatest risk for the development of sion, although present in today’s patient, is unusual de-
spite the predicted prevalence in this predominantlyHIVAN has increased substantially and, not surprisingly,
so have both the incidence of HIVAN and the prevalence black population. Thus the diagnosis of HIVAN would
be distinctly unlikely in the presence of telescoped,of HIV-positive patients in the population with end-
stage renal disease (ESRD). Since HIVAN is most often highly active urinary sediment, in a white patient, and
in patients with small end-stage kidneys.observed in the urban setting, nephrologists in other
locations might be unaware of the profound impact that The value of renal biopsy in the diagnosis of HIVAN
remains somewhat controversial in the general medicalHIVAN has had on large population centers. This Forum
is intended to persuade the reader that we are in the community but should be apparent to nephrologists. Al-
though the patient’s clinical course can be highly sugges-midst of a national epidemic of HIVAN and to address
some important questions. (1) What is HIVAN? (2) Is tive of HIVAN, biopsy confirmation is very important.
Even when a patient presents with the “classic” clinicalHIVAN a significant problem? (3) What is the cause of
HIVAN? (4) Is there any hope for effective therapy? features of HIVAN, the clinical suspicion is only pre-
dictive of the biopsy diagnosis in 55% to 60% of patients
What is HIVAN? [25]. Thus, to distinguish HIVAN from other forms of
renal disease in HIV-seropositive patients, a renal biopsyIn hospitals that serve communities with a high HIV-1
prevalence, the coexistence of seroposivity and/or AIDS is required.
The key histopathologic features of HIVAN are thewith renal insufficiency is common. Not all of these pa-
tients, however, have HIVAN. Many patients, particu- coexistence of focal segmental glomerulosclerosis (FSGS),
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Fig. 1. Histologic appearance of HIVAN on a renal biopsy. The combination of microcystic tubulointerstitial disease with FSGS of the collapsing
variant is diagnostic of HIVAN. Sections are stained with PAS and magnification is 1253 on the left and 2503 on the right.
Table 1. Glomerular diseases diagnosed by renal biopsy in 136 consecutive HIV-positive patientsa
Type of glomerular disease N 5 127 Type of tubulointerstitial disease N 5 9
Focal segmental sclerosis 88 Interstitial nephritis 5
Membranoproliferative GN 13 Acute tubular necrosis 3
Minimal change disease 6 Malignant lymphoma 1
Membranous glomerulopathy 5
Lupus-like nephritis 4
Amyloidosis 4
Acute postinfectious GN 2
Focal segmental necrotizing GN 1
Hemolytic-uremic syndrome 1
IgA nephropathy 1
Immunotactoid glomerulopathy 1
End-stage kidney 1
a Adapted from Ref. 25
often with glomerular collapse, and a distinctive tubulo- illustrates, diagnoses other than HIVAN confirmed in
interstitial disease that is termed microcystic (Fig. 1). HIV-1-positive patients include allergic interstitial ne-
Microcystic distortion involves enough tubule segments phritis, membranoproliferative glomerulonephritis, post-
to increase kidney size by as much as 25% but does not infectious glomerulonephritis, and many others [23–25,
lead to the massive enlargement of the kidney that is 40]. Since specific therapy might be administered for
typical of macrocystic diseases like adult polycystic kid- some of these other renal diseases, the biopsy is particu-
ney disease. D’Agati and Appel recently reviewed in larly helpful in generating a rational therapeutic strategy.
detail glomerular lesions associated with HIV infection Ancillary histologic studies provide some insight into
[25]. Many glomeruli are globally sclerotic and are often pathogenesis. The immunofluorescence is most remark-
seen interspersed among those that have segmental or
able for the absence of specific findings. Occasionally,collapsing sclerosis. Collapsing FSGS, however, is not
IgG, IgM, and/or C3 can be found in glomeruli, presum-pathognomonic for HIVAN, as it has been reported in
ably as a result of protein trapping. Rare patients havepatients who are HIV-1 seronegative [40]. Similarly,
been reported as having IgA deposition [41], but this isFSGS is not exclusive to HIVAN and can be seen both
a very unusual finding. Electron microscopy is similarlyas an idiopathic FSGS and in heroin nephropathy. The
striking for its lack of findings; with rare exceptions [41,combination of FSGS (particularly the collapsing vari-
42], immune complexes are absent. Furthermore, theant) with microcystic distortion in an HIV seropositive
patient, however, establishes the diagnosis. As Table 1 juxtaposition of glomerular basement membranes re-
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sulting from collapse of the capillary loops is easily visible cause of ESRD in this population, affecting 41% of the
at the light microscopic level. Thus HIVAN is not a patients; hypertension is second at 28%. The fourth most
disease generally associated with immune-complex de- common diagnosis, FSGS, a disease most would consider
position or complement activation, and the diagnosis can as common and important in blacks, represents only 3%
be established by standard light microscopy. of the new cases of ESRD and is now well behind HI-
Once HIVAN develops, it rapidly progresses to ESRD; VAN in incidence in this population.
renal survival is measured in weeks to months [38]. For Because HIVAN cases occur in a segment of the popu-
patients on dialysis, the mortality rate approaches 50% lation at risk for AIDS, we need to understand national
per year [38]. Recent reports suggest a slightly slower trends in the AIDS epidemic to anticipate future trends
progression to ESRD [43], and individual patients have in HIVAN. The CDC has carefully recorded the cumula-
been reported who have had little progression after as tive AIDS cases since the start of the epidemic in 1983.
long as two years. These are exceptional cases, however, In 1983, AIDS was a disease almost exclusive to San
and recent studies continue to suggest a very aggressive Francisco and New York (Fig. 2, top left). By 1985, other
disease process. For example, Burns et al reported that localized centers were in evidence including Los Angeles
a group of patients with HIVAN progressed rapidly from and Miami, but with few exceptions, the disease was
relatively normal renal function (mean serum creatinine, bicoastal (Fig. 2, top right). By 1989, most urban centers
1.5 mg/dl) to ESRD within six months of diagnosis [44]. were reporting an increasing accumulation of cases (Fig.
Whether this rapid progression represents the aggressive- 2, bottom left) and by 1995, almost every state with large
ness of the renal disease process or an effect of the underly- urban centers reported significant numbers of accumu-
ing HIV infection remains unclear. Routine screening lated cases of AIDS (Fig. 2, bottom right).
for proteinuria followed by a renal biopsy is not per- The incidence of new AIDS cases also varies dramati-
formed in most AIDS clinics and, as a result, we might cally by geographic location (Fig. 3). The Dakotas have
be missing a large number of patients earlier in their a rate of less than 2/100,000 population, the lowest in the
clinical course whose pre-ESRD interval might be longer. nation. This is in striking contrast to an incidence of 30.4
In summary, HIVAN is a disease that affects predomi- new cases/100,000 population in California, 33.5 in Geor-
nantly HIV-seropositive blacks who present with pro- gia, 33.9 in Louisiana, 34.0 in Connecticut, 39.7 in Dela-
teinuria. The diagnosis, suggested by a low CD41 cell ware, 44.7 in Maryland, 45.5 in New Jersey, 51.7 in Florida,
count in patients with normal to enlarged kidneys, is 59.7 in Puerto Rico, and 68.3 in New York (Fig. 3).
made by renal biopsy and cannot be inferred from the In urban centers the incidence is even more striking;
clinical course alone. Histologically, patients often have Washington, DC, reported 227.7/100,000 population and
the collapsing variant of FSGS with coexistent global
some boroughs of New York City documented more
glomerulosclerosis combined with microcystic tubuloin-
than 2,000 new cases/100,000 population (Fig. 4).terstitial disease. HIVAN progresses rapidly to ESRD
One of the major changes in the AIDS epidemic hasand is associated with a very high mortality rate, probably
been its evolving effect on the black and Hispanic com-reflecting the underlying, late stage of AIDS.
munities. In the early 1980s, the AIDS epidemic predom-
inantly involved white homosexual men. Over the pastIs HIVAN a significant problem?
five years, AIDS has disproportionally affected urbanThe response to this question depends on one’s geo-
black and Hispanic populations. While blacks and His-graphic location. If the patient population comprises a
panics constitute only 12% each of the US populationsignificant number of black or Hispanic patients and
(Fig. 5, right panel), at present they constitute 42% andAIDS is prevalent, the increase in HIVAN is well known
19% of patients with AIDS, respectively (Fig. 5, leftto the nephrologists in that community. On the other
panel). The percentage of blacks that represents newhand, if the patient population is predominantly white
AIDS cases also has continued to increase (Fig. 6). Asand AIDS is a low-prevalence disease in the community,
of 1995, there were more new cases of AIDS reportedHIVAN appears only rarely if ever. Although concen-
in blacks than whites.trated in urban centers, HIVAN has emerged as a disease
With the establishment of prevention programs andof national importance. According to the USRDS, the
the first effective treatment regimens for AIDS usingnumber of cases of HIVAN has increased at a rate of
combinations of highly active antiretroviral therapy30% each year, from 295 cases in 1991 to 951 cases in
(HAART), the CDC had detected a reduction in overall1996 [45], the most recent year for which statistics have
AIDS mortality rates. As reported by the CDC, one-been reported. Even assuming that there is no underre-
year mortality rates in whites and blacks have declinedporting of this disease, HIVAN is now the third leading
since the introduction of effective therapy in 1995 (Fig.cause of ESRD in blacks from the ages of 20 to 64,
7). With this optimistic finding, it would be tempting foraccounting for 10% of new cases of ESRD nationally
[38, 39]. Not surprisingly, diabetes remains the leading us to conclude that a similar reduction in HIVAN should
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Fig. 3. AIDS rates or incidence per 100,000 population as of 1996. Light gray indicates a rate of 0–9.9 cases of AIDS/100,000 population, white
a rate of 10.0–29.9 cases of AIDS/100,000 population, and dark gray a rate of 30 or more cases of AIDS/100,000 population. Data provided by
the Centers for Disease Control (CDC; Atlanta, Georgia, USA).
be expected. Unfortunately, close scrutiny of the avail- exert a profound influence on the national ESRD pro-
gram in the future.able data strongly suggests the opposite.
What is the likely incidence of HIVAN in the future?
What causes HIVAN?The best assessment of the potential for new cases comes
from the data that address the size and characteristics Although the exact molecular mechanisms responsible
of the pool at risk for developing HIVAN. If the pool for HIVAN remain unclear, a great deal of progress has
of patients is increasing, then it is reasonable to anticipate been made in our understanding of its pathogenesis. The
that the incidence of new cases of HIVAN will similarly remarkable racial predilection of HIVAN for blacks [19]
increase. Some of the best data for this risk pool come should provide clues towards an understanding of HI-
from the New York City Department of Health. As of VAN. Blacks are at greater risk for the development of
1996, the number of patients living with AIDS in New ESRD from all causes [46], so these insights likely will
York City was 128,700 (Fig. 8). Most of these patients be important to our understanding of the pathogenesis
were men (94,600) and 73% were black or Hispanic. of renal disease from other causes as well. In this regard,
The majority of these patients contracted the virus by the near absence of HIVAN in the white population
intravenous drug use. This is the very pool at risk for strongly suggests that genetic cofactors are required for
HIVAN, and unless dramatic changes alter these demo- the development of HIVAN in blacks.
graphics, or HAART therapy alters the course of renal There is a clear precedent for genetic factors in HIV-1
disease, the incidence of HIVAN can be expected to pathogenesis. Individuals who are homozygous for a de-
continue to climb dramatically. Thus, HIVAN is a sig- letion mutation in the recently described CCR5 HIV-1
coreceptor appear to be protected from HIV-1 infectionnificant cause of ESRD now and will likely continue to
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Fig. 4. Cumulative AIDS case rates per 100,000 pop-
ulation in New York City by zip code. Expressed per
100,000 population. Data are provided by the New
York City Department of Health, Office of AIDS
Surveillance.
[47]. Individuals who are heterozygous for this deletion tends to be enlarged. Thus proliferation is a significant
component of the pathogenesis. In addition, apoptosismutation appear to have a slower progression to AIDS
has been observed both in humans [52] and experimental[48]. Furthermore, individuals with polymorphism in
animals transgenic for HIV-1 genes [53] and likely con-some of the other HIV-1 coreceptors including CCR-2b
tributes to the disease process. Since the kidney is en-[48] or the CXCR-4 ligand SDF1 [49] appear to have
larged, however, proliferation must predominate overslower disease progression as well. The CCR5 deletion
apoptosis, and it is always possible that the two aremutation is present in approximately 1% of whites of
linked, with proliferation leading to increased apoptosis.northern European ancestry. This mutation arose in Eu-
Finally, glomeruli manifest both focal and global sclero-rope approximately 600 years ago, presumably under
sis, and tuft collapse seems to be a key characteristic.pressure from an environmental infectious agent, possi-
Visceral epithelial disease could account for both FSGS,bly the plague, and is found exclusively in Caucasoids
when involvement is focal, and for glomerular collapse,[50, 51].
when the disease is more widespread and aggressive.The high incidence of intravenous drug use in patients
Extracellular matrix deposition in glomeruli occurs as awith HIVAN also has suggested a potential environmen-
result of either an increase in synthesis, a reduction intal cofactor. In the urban HIV-seropositive population,
degradation, or both [54, 55]. This alteration in extracel-however, the prevalence of intravenous drug use is 50%,
lular matrix metabolism might be the primary cause of
and there does not appear to be a difference in the the disease, but this seems unlikely. A more plausible
history of intravenous drug use between those who do explanation is that the changes in extracellular matrix
or do not have renal disease. Therefore, although intra- metabolism are secondary to epithelial and/or mesangial
venous drug use has been considered a risk factor for cell injury. Thus, glomerular and tubular epithelial cells
HIVAN in the past, this relationship might simply reflect appear to be the most likely disease targets of HIV-1
the coexistence of a high prevalence viral transmission infection, whereas changes in the extracellular matrix are
behavior that is associated with HIV infection but not more likely to represent secondary responses to injury.
causal in the development of HIVAN. How could systemic HIV-1 infection account for the
The pathologic features of HIVAN provide potential extensive epithelial damage observed in the kidney? The
clues into its mechanism. HIV-associated nephropathy pathogenesis of HIVAN has been reviewed recently [24,
is one of the few progressive diseases of the kidney where 56]. Since infection with HIV-1 is the one known unifying
risk factor, the most likely hypothesis is that HIV-1 eitherthere is no reduction in renal size and, in fact, the kidney
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Fig. 5. Relative contribution of AIDS cases by race/ethnicity reported in 1996 compared to the estimated race/ethnicity composition of the United
States population. Blacks constitute only 12% of the US population (right panel) but account for 42% of patients with AIDS (left panel ). Hispanics
also have a disproportionate number of AIDS cases (19%), while accounting for only 12% of the US population. Data provided by the CDC.
Fig. 6. Percentage of new AIDS cases by race/eth-
nicity from 1983 to 1996 as reported by the CDC. As
of 1996, new cases of AIDS in blacks exceeded the
number of new cases in whites.
directly or indirectly produces HIVAN. Following acute models. These “indirect” effects of the virus in turn might
induce renal disease. Evidence to the contrary exists asHIV-1 infection, a steady state develops between active
viral replication and T-cell turnover [57–60]. The im- well, however. Other diseases of altered cytokine pro-
duction (rheumatoid arthritis and lupus, for example)mune response generated to this highly dynamic infec-
tion leads to a characteristic pattern of cytokine and do not result in renal lesions with the same features
as HIVAN. Furthermore, an explanation for the racialgrowth-factor dysregulation in which TH1 cytokines (IL-2
and interferon gamma) predominate early, but later TH2 predisposition to HIVAN is not readily apparent if the
disease is due to an alteration in cytokine milieu. Thuscytokines (IL-4, IL-5, IL-6, and IL-10) are increased [61,
62]. In addition, growth factors such as TGF-b [63] and other explanations seem more plausible, particularly in
view of some of the experimental animal data.bFGF [64] are also increased in humans and in murine
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Fig. 7. Mortality from HIV infection in 25- to
44-year-olds by race and gender. The death rate
began to plateau between 1994 and 1995 with
the introduction of protease inhibitors. Data pro-
vided by the CDC.
The HIV transgenic mouse models have been ex- to involve a direct effect of the virus on the kidney.
Direct deleterious effects of HIV-1 on renal tissues couldtremely important in providing insights into pathogene-
sis. When placed into mice as a transgene, a replication- include infection by an unknown mechanism or exposure
to circulating viral gene products or to gene productsincompetent HIV-1 proviral construct (gag/pol-deleted
pNL4-3) produces a disease in mice that is identical to released from infected infiltrating cells [see review of
pathogenesis in Ref. 56]. Renal epithelial infection byHIVAN in humans. This observation provided the first
clear demonstration that HIV-1 is responsible for HI- HIV-1 is a plausible hypothesis, but evidence exists both
for and against this hypothesis. In support of renal epi-VAN and that the renal lesion is not simply heroin ne-
phropathy (Fig. 9A). Additional recent data from the thelial cells as a target for HIV infection, Cohen et al
examined the presence of HIV-1 DNA in renal tissuetransgenic mouse model reveal that HIV-1 expression
can be detected in renal epithelial cells. Because both obtained by percutaneous renal biopsy. Using in-situ
hybridization methods, this group noted one tubule thatglomerular and tubular epithelia appear to be the main
targets of HIV-1-induced disease, the expression of suggested the presence of HIV-1 DNA [65]. Subse-
quently, Kimmel and coworkers detected HIV-1 DNAHIV-1 in the same cell type strongly suggests an etiologic
link between intracellular expression of HIV-1 and HI- in microdissected glomeruli from renal biopsy material
[66]. These data suggest the presence of HIV-1 DNA inVAN (Fig. 9, panel B). Nonetheless, because expression
of the HIV-1 transgene is also observed in other tissues, renal cells, but this information does not define the cell
type potentially infected, does not exclude the presenceincluding lymphoid cells, spleen, and muscle, a pathoge-
netic role for the altered systemic milieu cannot be ex- of contaminating, infected T-cells or macrophages in the
renal biopsy material, and does not establish the pres-cluded. To address this issue, kidneys from transgenic
mice were transplanted into non-transgenic littermates, ence of replicating virus in the kidney.
Cell culture studies also have failed to provide defini-and the reciprocal transplantation was performed [53].
HIV-associated nephropathy develops only in transgenic tive evidence for or against renal infection. Green et al
reported that glomerular endothelial and mesangial cellskidneys transplanted into a normal mouse background;
normal kidneys remain unaffected even when trans- could support a very modest infection using a cloned
laboratory strain HIV-1IIIB and a primary isolate HIV-planted into a transgenic littermate. These data provide
compelling evidence that expression of HIV-1 in the 1MB [67]. The amount of virus measured in these studies,
however, was near the lower limits of detection by thetarget cells appears to be the critical step for inducing
HIVAN in the mouse. p24 assay that was used. Alpers et al reported mesangial
cells to be resistant to infection by a variety of clonedAs a result of this evidence from the murine model,
the idea that the systemic milieu induces HIVAN in HIV-1 strains [68]. Ray and colleagues evaluated the
ability of primary renal tubular epithelial cells isolatedhumans seems a less likely mechanism for the pathogene-
sis of this disease. A more likely explanation would seem from the urine of children with HIVAN to support a
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Fig. 8. The risk pool for HIV-associated ne-
phropathy. The estimated number of New
Yorkers living with HIV infection or AIDS
as of 1996, reported by the New York City
Department of Health, Office of AIDS Sur-
veillance. The greatest number of patients liv-
ing with HIV/AIDS were African-American
males infected by HIV-1 through intravenous
drug use.
Fig. 9. Histologic appearance of renal disease and HIV expression in the transgenic mouse line Tg26. (A) Kidneys from transgenic mice manifest
all the features found in humans, including FSGS and global sclerosis combined with microcystic tubulointerstitial distortion. (B) In-situ hybridization
for HIV mRNA demonstrates expression in epithelial cells and in glomerular podocytes.
primary infection [69]. Again, the p24 values were so gests a plausible explanation for the route of infection.
Whether these HIV-1 receptors are found on the celllow that the results were not definitive. Recently, Con-
aldi and coworkers made an important contribution by surface in sufficient numbers to confer susceptibility to
infection in vivo remains unclear, however. In summary,proving that the low levels of infection observed with
in-vitro infection resulted in HIV-1 replication with de- studies increasingly suggest that low levels of HIV-1 in-
fection of renal cells can be achieved in vitro. They dotection of gag RNA by RT-PCR [70]. In addition, they
detected both CD4 and CXCR-4 transcripts by RT-PCR not, however, provide definite evidence for direct renal
infection in vivo.in renal mesangial and epithelial cells; this finding sug-
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Can HIVAN be treated effectively? Aggressive antiviral therapy might be a more appro-
priate strategy for HIVAN, particularly if viral replica-One would hypothesize that therapy directed to the
tion occurs in renal tissue. Independent of the issue ofessential pathogenesis would be most effective, but until
pathogenesis, many patients with HIVAN are not onour understanding of HIVAN improves, many of the
maximal antiviral regimens. We found that patients withcurrent approaches are empiric. Strategies for therapy
HIVAN have viral loads that are often quite elevatedhave been reviewed recently [71]. A variety of strategies
[38]. Whether patients with HIVAN represent a particu-have been tried including immunosuppression with corti-
larly difficult-to-treat subset or whether the kidney pro-costeroids or cyclosporine, the use of angiotensin-con-
vides a protected reservoir of replicating virus remainsverting-enzyme inhibitors, and antiviral regimens.
unknown. Surprisingly, a randomized trial to look atSmith et al first explored the use of corticosteroids
HAART therapy for HIVAN has not yet been done.for the treatment of HIVAN [72, 73]. They treated 20
The increasing importance of this disease to the ESRDpatients; most had a biopsy-proven diagnosis of HIVAN.
population emphasizes the need to bring HIVAN andThe patients’ serum creatinine levels were greater than
the renal complications of HIV infection to the attention2 mg/dl, and urinary protein was greater than 2 g/24
of the National Institutes of Health’s (NIH) Office ofhours. They administered prednisone, 60 mg/day, and
AIDS Research. The Office of AIDS Research (OAR)analyzed the patients’ response following 2 to 14 weeks
was established to set priorities for HIV-related researchof treatment. Of 19 patients, 17 had at least a 20% de-
funding. The OAR’s inception was in direct responsecrease in serum creatinine, and 12 of 13 had a decrease
to concerns raised by several constituencies, includingin urinary protein excretion. Only 2 patients, however,
AIDS activists, that a “Manhattan project” approachsurvived more than one year without progressing to
with a central organization and a single disease focusESRD. This result does not differ significantly from his-
could accomplish more than the traditional oversight andtoric data or results from control groups in recent trials.
funding mechanisms administered through the variousThus the value of corticosteroids in treating HIVAN
institutes. Thus, the 1.5 billion dollar budget was mar-
remains unproved.
shaled under a single entity and charged with the respon-
Angiotensin-converting-enzyme (ACE) inhibitors also
sibility of setting global priorities. The assumption was
have been suggested as potentially beneficial for the
that funding under a specific office’s supervision rather
treatment of HIVAN [44, 74, 75]. Kimmel et al, in a
than that of the traditional structure would be more
nonrandomized trial of 18 patients receiving antiviral effective and priority driven. Whether this strategy will
therapy, administered captopril, 25 mg three times daily, fulfill expectations remains unclear. What is clear, how-
to nine patients; nine patients received their antiviral ever, is that the OAR structure places an additional
regimen alone [74]. The patients had advanced renal barrier to progress on diseases of importance to the ne-
disease with a mean serum creatinine of 3.4 mg/dl and phrology community such as HIVAN and the many toxic
a urinary protein-to-creatinine ratio of greater than 5. nephropathies related to antiviral therapy. It is our re-
Most had an AIDS-defining condition, with the highest sponsibility to ensure that the OAR keeps pace with
CD4 count being 235 cells/ml (one patient). The mean the rapidly changing epidemic of HIVAN in the ESRD
time for progression to ESRD was 37 6 5 days in controls patient population and the many renal complications
and 156 6 71 days in treated patients. This study sug- associated with HIV-1 infection and its therapy. Unless
gested that ACE inhibitors are effective but also raised highly active antiretroviral therapy alters progression of
the possibility that earlier intervention might be more renal disease in infected patients, we will continue to see
appropriate. a dramatic increase in the number of HIVAN patients
Burns and colleagues evaluated 20 patients with coming to dialysis in the next five years. Therefore, we
biopsy-proven HIVAN [44]; intervention occurred much must support fundamental research in order to make
earlier than in the Kimmel study. Control and treated substantive advances in our understanding of pathogene-
patients had serum creatinine levels of approximately sis, and we must continue to explore novel therapeutic
1.5 mg/dl. Patients receiving fosinopril, 10 mg daily for approaches.
six months, had a serum creatinine of 1.7 6 0.7 mg/dl at
the end of the treatment period. In contrast, controls
QUESTIONS AND ANSWERS(those who did not take the ACE inhibitor) progressed
rapidly to a creatinine level of 7.0 6 3.0 mg/dl. Although Dr. Nicolaos E. Madias (Chief, Division of Nephrol-
an intriguing finding, the lack of randomization and the ogy, New England Medical Center, Boston, Massachu-
definition of the control group (those who were unwilling setts): What other pathologic changes do mice transgenic
to take converting-enzyme inhibitors) made this study for the HIV-1 gene exhibit?
less definitive and underscores the need for an appropri- Dr. Klotman: We sustain the line as heterozygotes,
because the homozygous mice manifest growth retarda-ately designed randomized trial.
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tion and develop a wasting syndrome leading to death renal material from the transgenic model of HIVAN
suggest about the importance of cytokines in this dis-within six weeks. The heterozygous mice also develop
cataracts, occasional papillomatous skin lesions, hepato- ease?
Dr. Klotman: The tubuloreticular inclusions seen insplenomegaly, and lymphadenopathy. The incidence of
the skin disease is much less in our current colony than humans are nonspecific findings thought to reflect circu-
lating levels of interferon. Patients with lupus nephritis,at the NIH. We also have evidence that the transgenic
mice are more susceptible to infection with other patho- for example, have tubuloreticular inclusions. Although
present in humans, the implication from the mousegens, such as cryptococcus.
Dr. Madias: Could you comment on the possible model is that tubuloreticular inclusions might not be
critical for the development of the histopathologicmechanisms that would lead to such high susceptibility of
African-Americans to HIVAN, and in particular, males? changes that we refer to as HIV-associated nephropathy.
Our reciprocal transplantation studies between transgenicDr. Klotman: This is one disease in which genetic
risk factors are clearly responsible. We obviously do not and nontransgenic littermates also suggest that the cyto-
kine milieu is less important than is the expression ofknow yet what they are, but presumably an understand-
ing of these differences might give us insight into the HIV-1 in the kidney. This suggestion does not exclude
the possibility that alterations in cytokines affect diseasegeneral risk of blacks for renal diseases in general. Rea-
sonable possibilities include genetic differences in the risk or progression.
Dr. Vivette D’Agati (Department of Pathology, Co-ability to support the viral life cycle in renal cells such
as viral entry, transcription, or splicing; genetic differ- lumbia Presbyterian Medical Center, New York, New
York): In recent years, we have observed an overallences in responses to the virus; or differences in disease
progression factors, including systemic cytokines and reduction in the number of endothelial tubuloreticular
inclusions detectable in our renal biopsy specimens ofgrowth factors. Many more possibilities exist as well. It
is unclear whether African-American males really are HIVAN compared to the late 1980s. I suspect that this
trend reflects the recent introduction of newer and moremore susceptible than females to HIVAN. The higher
incidence in males might be similar to the issue regarding effective antiretroviral agents leading to reduced viral
burden and corresponding modulation of the cytokineintravenous drug use; that is, the incidence might simply
reflect the demographics of the HIV epidemic. milieu.
Dr. Klotman: Indeed, since the introduction of prote-Dr. Madias: As you know, collapsing focal glomerular
sclerosis does occur in the absence of HIV infection. ase inhibitors, we have been able to effect a major and
sustained reduction in the viral burden of most patients.Usually it is preceded by a viral-like illness, it has a
predisposition for African-Americans, and it can recur Dr. Jonathan Winston (Department of Medicine, Mt.
Sinai School of Medicine): What is the prevalence ofafter transplantation. Does this observation suggest that
different infectious agents lead to the same pattern of HIVAN in the general HIV clinic population?
Dr. Mokrzycki: We recently reviewed the prevalenceinjury? What are the implications for our current views
on the pathogenesis of HIV nephropathy? of HIVAN in the outpatient population at Jacobi Hospi-
tal, Bronx, New York, and found it to be low, 1.9%.Dr. Klotman: I think it is likely that there will be
common patterns of injury in response to environmental Other interesting epidemiologic findings were that male
gender is not an independent risk factor for HIVAN andfactors, particularly infectious diseases. In addition, we
have not excluded the possibility that environmental risk that the risk of HIVAN in Hispanics is similar to that
in whites.factors also play a role in the pathogenesis of HIVAN.
The development of Kaposi’s sarcoma in patients who Dr. Eric Langhoff (The Pennsylvania State University
College of Medicine, Hershey, Pennsylvania): Your HIVare both seropositive and infected with HHV8 suggests
that HHV8 is a cofactor for the development of this transgenic mouse model demonstrates that HIV-1 ex-
pression is essential for the development of nephropathycomplication of AIDS. A similar co-pathogen might exist
and, with the high incidence of intravenous drug use as in immune-competent mice. Is it known whether similar
changes occur in T-cell-deficient mice or in mice withthe mode of transmission of HIV-1 in patients with renal
disease, it is not difficult to understand how this could deficient apoptosis pathways?
Dr. Klotman: In collaboration with Joe Bryant at theoccur. But the transgenic mouse model, the similar renal
disease entity in feline immunodeficiency virus infection, NIH, we have put the HIV-1 transgene on both nude and
beige mouse backgrounds. Both strains develop HIVANand the presence of renal disease in primates with SIV
suggest that a common infectious co-pathogen is less [56]. We concluded that expression of HIV gene products
in renal cells was the primary cause of the disease in thelikely in HIVAN than in Kaposi’s sarcoma, for example.
Dr. Michele Mokrzycki (Department of Medicine, mouse model. But we cannot exclude the possibility that
in humans infected T-cells or macrophages expose theAlbert Einstein College of Medicine, New York, New York):
What does the absence of tubuloreticular lesions in the kidney to viral gene products. We are now crossing the
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transgenic mouse onto a number of different back- pressed on renal epithelial cells and podocytes or that
an already-identified receptor is induced in susceptiblegrounds to explore many of the issues that you raise.
Dr. Paul L. Kimmel (Division of Renal Disease, patients under certain conditions. It is also possible that
novel entry mechanisms exist in the kidney as well. Pro-George Washington University Medical Center, Washing-
ton, DC): Several chemokine receptors have been identi- liferating T-cells clearly are more susceptible to inducing
a productive infection than are resting T-cells. The reasonsfied and have been shown to determine tropism of HIV
[62, 76, 77]. Have similar chemokine receptors been dem- for this are complex, however, and include post-entry
events such as the extent of complete reverse transcrip-onstrated in tubular, interstitial, or endothelial cells in
renal tissue? tion and proviral integration. As a result, it is difficult
to predict the role of proliferation in renal cell infection.Dr. Klotman: As you know, at least nine other second
receptors have been identified that mediate HIV-1 enve- Dr. Madias: Dr. Ray, could you please comment on
the clinical features of HIV-associated nephropathy inlope fusion with the cell membrane. The CCR5 receptor
on macrophages and CXCR4 receptor on T-cells are children as compared with adults?
Dr. Ray: In children, HIVAN is usually a late compli-required, in concert with CD4, for viral entry. In addi-
tion, CD4-independent pathways might exist in dendritic cation of AIDS after some other AIDS-defining condi-
tion has occurred. But progression does not appear tocells [78] and several studies have demonstrated the abil-
ity of lentiviruses to interact with coreceptors indepen- be as rapid as in the adult. In addition, children often
have FSGS and mesangial involvement, and the role ofdent of CD4 [79, 80]. Using immunostaining of the renal
epithelium, Alpers’ group has shown that these receptors HIV in these processes needs to be better defined.
Dr. Madias: To return to the patient, there is clearare not present in primates infected with SIV or in nor-
mal human tissue [81]. But these findings do not exclude evidence of renal functional improvement after restart-
ing antiviral therapy. Do you think that the patient re-the possibility that receptors are induced under certain
pathologic conditions or that they are present at very sponded to antivirals because there was replicating virus
in the kidneys, or do you think that his improvementlow levels. Your group has shown that renal cells also
can generate chemokines that might influence viral entry reflected resolution of a superimposed different cause
of renal dysfunction?(abstract, Kimmel et al, J Am Soc Nephrol, 4:279, 1993).
Dr. Patricio E. Ray (Children’s Research Institute, Dr. Klotman: I would like to believe that the patient
responded to antiviral treatment, but this case points outChildren’s National Medical Center, Washington, DC):
Chemokines also might recruit infected cells that might the need for controlled trials. It is equally likely that the
patient had an active inflammatory injury superimposedallow viral uptake in the kidney through a different
mechanism. For example, the Duffy antigen chemokine on the background of HIVAN. That injury simply might
have resolved. With the extent of the structural damagereceptor is consistently expressed in renal capillaries
from African-American children with HIVAN [82], al- in HIVAN, it is hard to believe that there would be a
dramatic response late in the disease process, and antivi-though approximately 70% of African-American chil-
dren do not express the antigen on their red cells [83]. ral therapy might be useful only in the early stages of
HIVAN or during its development. It would be interest-Thus, racial differences in chemokines could lead to very
different manifestations. ing to postulate in this case that the virus induced an
interstitial nephritis that responded to antiviral therapy.Dr. Kimmel: We also are looking at chemokine recep-
tors and their regulation in the pathogenesis of HIVAN. Unfortunately, even with therapy, he never had unde-
tectable levels of viral RNA.Do you think that there are protected sites of viral repli-
cation, and are there nephropathic or renal tropic strains Dr. Godfrey Burns (Division of Nephrology, St. Vin-
cent’s Hospital, New York, New York): We have lookedof HIV?
Dr. Klotman: These are very important questions. at patients early in the course with creatinine levels under
2 mg/dl [44]. In this group, patients responded well toWe have some strong evidence that HIV-1 gains entry
into renal cells, and that finding would be consistent with converting-enzyme inhibition and did not progress in the
six months of follow-up, most likely because they didyour PCR studies. We also are evaluating the quasispe-
cies of HIV-1 to see whether there is any selective pres- not have extensive structural damage.
Dr. Klotman: There is no question that your study issure on the virus or compartmentalization. That HIVAN
occurs late in the disease process would suggest the po- very promising, but we still need to have a randomized
trial. It would also be very interesting to evaluate thetential for shifts in viral quasispecies, but we have just
begun these studies. renal histology again in your patients who received treat-
ment.Dr. Ray: What is the most likely mechanism of infec-
tion, and would only proliferating cells become infected? Dr. Madias: Does anyone in the audience have docu-
mented experience of improvement in renal function inDr. Klotman: If HIV-1 can infect renal tissue, then I
would expect that a not-yet-identified receptor is ex- patients with HIV-associated nephropathy in the ab-
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sence of superimposed, obvious causes of renal insuffi- HIVAN, then we plan for a hemodialysis access as soon
as possible. What we try to avoid is discharging the pa-ciency, for example, volume depletion or acute intersti-
tial nephritis? tient only to find that the next encounter is in the emer-
gency room when the patient is in need of emergencyDr. T.K.S. Rao: (State University of New York, Brook-
lyn, New York): We have had a group of patients with hospitalization and acute dialysis without a functioning
access.very rapidly progressive disease who responded dramati-
cally to steroids. Dr. Madias: Dr. Ray, I was interested in your com-
ments on cellular proliferation. As you know, the ubiqui-Dr. Ira W. Reiser (Brookdale University Hospital and
Medical Center, Brooklyn, New York): We also have tous isoform of the Na1/H1 exchanger, so-called NHE-1,
has been implicated in growth and proliferation. Benosseen remarkable responses to steroids in some patients.
Dr. Klotman: Perhaps the steroid-responsive patients and colleagues have shown that in astrocytes, HIV enve-
are those who have significant interstitial inflammation. lope glycoprotein gp120 stimulates the NHE-1, and they
Obviously we need more randomized trials. But unless have implicated this change in cellular dysfunction [84,
the patients have biopsy-proven HIVAN, we know that 85]. Are there any studies on the effects of HIV products
they could have any number of other lesions that are on renal cell transporters and function?
steroid responsive. Dr. Ray: I am not aware of any study addressing
Dr. D’Agati: We have seen biopsy-documented cases this topic in renal cells. However, the exposure of renal
of HIVAN from Harlem Hospital that were treated with epithelial cells to HIV-1 or HIV gene products is more
steroid therapy and had a short-term improvement in likely to damage or kill these cells rather than induce
renal function. Follow-up renal biopsies performed sev- proliferation. Our findings in renal tubular epithelial cells
eral months after initiation of steroid therapy have dem- isolated from children with HIVAN and exposed to their
onstrated a marked reduction in the degree of interstitial own primary isolates suggest that HIV-1 induces cellular
inflammation and acute tubular injury. This response is injury or death, not necessarily by apoptosis [69]. More-
similar to that observed following steroid therapy in over, in HIV-transgenic mice, HIV-1 genes first induce
some forms of acute interstitial nephritis. renal epithelial injury, which is followed by a regenera-
Dr. Madias: Do you biopsy all patients before they tive proliferative response driven by cytokines that are
are enrolled into studies? released by injured cells and bound to the renal extracel-
Dr. Klotman: We do. I think these comments all argue lular matrix [64]. It is possible that during the process
for the need for renal biopsy for the diagnosis of HIVAN of HIV-1 infection or induction of renal epithelial injury,
if one plans on performing a study of natural history or the intracellular content of ions and/or NHE-1 activity
intervention. is altered. Several renal growth factors can induce
Dr. D’Agati: I believe renal biopsy is of value in this changes in Na1/H1 exchanger activity in renal epithelial
setting. Although HIVAN remains the leading biopsy cells; however, changes in Na1/H1 exchange activity are
diagnosis in HIV-infected patients at Columbia Presby- not strictly required for cell proliferation [86]. The role
terian Medical Center, we have observed a variety of of renal cell transporters in HIV nephropathy is an inter-
glomerular, vascular, and tubulointerstitial diseases in esting area of research that requires further study.
this population. These disorders include HCV-associated
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